<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic bone marrow transplantation (BMT) was carried out on a 5-year-old boy with <z:hpo ids='HP_0004810'>congenital hypoplastic anemia</z:hpo> (CHA), who did not respond to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> and who was displaying signs of progressive <z:mp ids='MP_0005639'>hemosiderosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Pretransplant preparation had to be modified because <z:hpo ids='HP_0002093'>respiratory failure</z:hpo> and <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> supervened </plain></SENT>
<SENT sid="2" pm="."><plain>This preparatory regimen consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> (2 mg/kg for four days), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (50 mg/kg for one day), and total body irradiation (750 rad) </plain></SENT>
<SENT sid="3" pm="."><plain>Hemopoiesis was completely restored and is still maintained 650 days after transplantation </plain></SENT>
<SENT sid="4" pm="."><plain>This is the second published report on the use of BMT to treat a patient with CHA, and it is the first time it has resulted in long-term survival </plain></SENT>
<SENT sid="5" pm="."><plain>BMT should be considered for patients with CHA who do not respond to <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
</text></document>